Return to company search top

TOKYO CHALLENGE 100 with Nippon Shinyaku Co.,Ltd.

Drugs that only Nippon Shinyaku can make, Future that only Nippon Shinyaku can create

About Nippon Shinyaku Co.,Ltd.

Based on the business philosophy “Helping people lead healthier, happier lives,” in our pharmaceutical segment, by focusing on our areas of specialty, we aim to become a company which provides quality and unique pharmaceuticals to help patients suffering from illnesses. Our areas of specialty for both R&D and marketing include urology, hematology, gynecology, otolaryngology and orthopedics. By implementing our own drug discovery research, licensing-in from other companies and product lifecycle management (PLCM), we are striving to speedily launch pharmaceuticals to help patients. Our drug discovery research is focused on the strategic fields such as urology and hematology, and on the elucidation of cause of new diseases.

Nippon Shinyaku Co.,Ltd. Challenges

Improvement of Pharmacokinetic Properties and Efficacy of Nucleic Acid Drug
We seek technologies to improve the pharmacokinetic properties of a nucleic acid drug, such as in vivo stability, prolonging blood circulation, tissue-specificity and cellular uptake.


Drug discovery seeds and technologies for intractable orphan diseases and hematological cancers
We are engaged in Open Innovation focusing mainly on drug-target discovery for intractable diseases and hematological cancers, and developing new technologies with higher motivation.


Digital medicine by Apps for Urinary system
We aim to create the value not only for patients who have been struggling to receive treatment but also with their families and medical staffs, through the new technology and treatment approach called “digital medicine”


Applications have been closed.

Corporate Profile of Nippon Shinyaku Co.,Ltd.

Company Name Nippon Shinyaku Co.,Ltd.
Business Overview Pharmaceuticals for medical homes, in-house drug discovery is concentrated in urology, hematology, intractable diseases and rare diseases. Cultivation of functional foods
Type of Industry Pharmaceutical
Collaboration results Jul. 2020 Fund investment results

1 billion yen invested in Biotech Fund newly established by Medical Incubator Japan Co., Ltd., an independent venture capital firm specializing in healthcare (headquarters: Minato-ku, Tokyo, President: Tsuji, "MIJ")

Mar. 2019 Collaboration results

Zogenix, Inc. (Headquarters: California, U.S.A., President and Chief Executive Officer: Stephen Farr) and ZX008, which is expected to be adaptive for Drabe syndrome and Lennox-Gasto syndrome, have an exclusive sales agreement in Japan.

Mar. 2017 Collaboration results

Delta-Fly Pharma Co., Ltd. (Headquarters: Tokushima City, President: Kiyoshi Ejima) acquires exclusive development and exclusive sales rights in Japan for DFP-10917, a recurrent and infunable acute myeloid leukemia (AML) treatment.